- Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
- Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
- Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
- Biohaven Announces Proposed Public Offering of Common Shares
- Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
More ▼
Key statistics
On Wednesday, Biohaven Ltd (BHVN:NYQ) closed at 33.79, 105.41% above the 52 week low of 16.45 set on Sep 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 34.48 |
---|---|
High | 35.10 |
Low | 33.44 |
Bid | 33.38 |
Offer | 34.00 |
Previous close | 34.17 |
Average volume | 1.63m |
---|---|
Shares outstanding | 88.29m |
Free float | 72.29m |
P/E (TTM) | -- |
Market cap | 3.02bn USD |
EPS (TTM) | -6.83 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 22:00 BST.
More ▼